Medicare Benefits Schedule - Item 73296

Characterisation of germline gene variants:

(a) including copy number variation in:

(i) BRCA1 genes; and

(ii) BRCA2 genes; and

(iii) one or more of the genes STK11, PTEN, CDH1, PALB2 and TP53; and

(b) in a patient:

(i) with breast, ovarian, fallopian tube or primary peritoneal cancer; and

(ii) for whom clinical and family history criteria (as assessed, by the specialist or consultant physician who requests the service, using a quantitative algorithm) place the patient at greater than 10% risk of having a pathogenic or likely pathogenic gene variation identified in one or more of the genes specified in subparagraphs (a)(i), (ii) and (iii);

requested by a specialist or consultant physician

Fee: $1,200.00 Benefit: 75% = $900.00 85% = $1,112.10

(See para PN.0.27 of explanatory notes to this Category)

• Previous - Item 73295
• Next - Item 73297

Items 73295, 73296, 73304, 73333, 73392, 73395, 73416 and 73419.

Patients who are found to have any form of affected allele should be referred for post-test genetic counselling as there may be implications for other family members. Appropriate genetic counselling should be provided to the patient either by the specialist treating practitioner, a genetic counselling service or a clinical geneticist on referral.

Items 73416 and 73392

The rapidly expanding field of genomic medicine has resulted in recognition of an increasing number of genetic causes of
cardiac diseases. Use of genomic testing methods that permit reanalysis of existing data for variants in newly described
clinically relevant genes are recommended/encouraged.

Related Items: 73295 73296 73304 73333 73392 73395 73416 73419